PL2106260T3 - Środki uwrażliwiające na insulinę i sposoby leczenia - Google Patents
Środki uwrażliwiające na insulinę i sposoby leczeniaInfo
- Publication number
- PL2106260T3 PL2106260T3 PL08700385T PL08700385T PL2106260T3 PL 2106260 T3 PL2106260 T3 PL 2106260T3 PL 08700385 T PL08700385 T PL 08700385T PL 08700385 T PL08700385 T PL 08700385T PL 2106260 T3 PL2106260 T3 PL 2106260T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- methods
- insulin sensitisers
- sensitisers
- insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89776907P | 2007-01-25 | 2007-01-25 | |
AU2007902013A AU2007902013A0 (en) | 2007-04-17 | Inhibitory compounds | |
US98433507P | 2007-10-31 | 2007-10-31 | |
US737607P | 2007-12-11 | 2007-12-11 | |
PCT/AU2008/000089 WO2008089521A1 (en) | 2007-01-25 | 2008-01-25 | Insulin sensitisers and methods of treatment |
EP08700385.1A EP2106260B8 (en) | 2007-01-25 | 2008-01-25 | Insulin sensitisers and methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2106260T3 true PL2106260T3 (pl) | 2018-06-29 |
Family
ID=39644028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08700385T PL2106260T3 (pl) | 2007-01-25 | 2008-01-25 | Środki uwrażliwiające na insulinę i sposoby leczenia |
Country Status (12)
Country | Link |
---|---|
US (3) | US8455432B2 (pl) |
EP (1) | EP2106260B8 (pl) |
JP (1) | JP5301465B2 (pl) |
CN (1) | CN101801375B (pl) |
AU (1) | AU2008209320B2 (pl) |
CA (1) | CA2676051C (pl) |
ES (1) | ES2660170T3 (pl) |
NO (1) | NO2106260T3 (pl) |
NZ (1) | NZ579229A (pl) |
PL (1) | PL2106260T3 (pl) |
PT (1) | PT2106260T (pl) |
WO (1) | WO2008089521A1 (pl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ579229A (en) | 2007-01-25 | 2011-07-29 | Verva Pharmaceuticals Ltd | Insulin sensitisers and methods of treatment |
US20200155558A1 (en) * | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
MX2014014316A (es) * | 2012-05-24 | 2015-07-06 | Verva Pharmaceuticals Ltd | Método de reducción de peso. |
NZ702645A (en) * | 2012-05-24 | 2016-08-26 | Verva Pharmaceuticals Ltd | A method of improving liver function |
AU2013202988B2 (en) * | 2012-06-29 | 2016-04-21 | NAIA Metabolic, Inc. | Method of improving liver function |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2994701A (en) | 1961-08-01 | Z-sulfamyr | ||
US2783241A (en) * | 1957-02-26 | S-acylimino-x-substituted-az-i | ||
US2554816A (en) | 1950-04-04 | 1951-05-29 | American Cyanamid Co | Heterocyclic sulfonamides and methods of preparation thereof |
GB795174A (en) | 1954-10-13 | 1958-05-21 | Upjohn Co | Heterocyclic sulphonamides |
US2835702A (en) | 1956-05-02 | 1958-05-20 | Merck & Co Inc | Benzene 1, 3 disulfonamides possessing diuretic properties |
US2978457A (en) | 1959-04-06 | 1961-04-04 | Merck & Co Inc | 5-acylamido-4-substituted-thiazole-2-sulfonamides having diuretic properties |
US3157572A (en) | 1961-01-06 | 1964-11-17 | American Cyanamid Co | Parenteral diuretic compositions of 5-acylimino-4-substituted-delta2-1, 3, 4-thiadiazolidine-2-sulfonamides |
US3668248A (en) * | 1964-09-30 | 1972-06-06 | Lilly Co Eli | 5-chloro-2,4-bis(sulfamoyl)fluorobenzene and 5-chloro-2,4-bis(chlorosulfonyl)fluorobenzene |
FR2468366A1 (fr) | 1979-10-31 | 1981-05-08 | Stoclet Alain | Medicament antiglaucomateux a base d'acetazolamide ou de methazolamide |
EP0096003B2 (de) | 1982-05-28 | 1994-06-15 | Ciba-Geigy Ag | Neue Sulfonyl(thio)harnstoffe, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und/oder Wachstumsregulatoren |
IT1224860B (it) | 1988-07-29 | 1990-10-24 | Istituto Chimico Internazional | Composti correlati all'acetozolammi de con attivita' inibitrice dell'anidrasi carbonica, utili in particolare nel trattamento del glaucoma |
GB2223166B (en) | 1988-09-29 | 1992-03-18 | American Cyanamid Co | Stable ophthalmic preparations containing methazolamide |
US4990523A (en) * | 1989-06-19 | 1991-02-05 | A. H. Robins Company, Incorporated | Treatment of chronic inflammatory joint disease with arylsulfonamides |
US5585377A (en) | 1990-04-09 | 1996-12-17 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
US5153192A (en) | 1990-04-09 | 1992-10-06 | Alcon Laboratories, Inc. | Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
US5378703A (en) | 1990-04-09 | 1995-01-03 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
US5225424A (en) | 1992-10-21 | 1993-07-06 | University Of Iowa Research Foundation | Methazolamide-derived carbonic anhydrase inhibitors |
US5519040A (en) | 1994-04-29 | 1996-05-21 | Allergan | Substituted thiazole sulfonamides as antiglaucoma agents |
TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
EP0869785B1 (en) * | 1995-11-17 | 2002-08-28 | PHARMACIA & UPJOHN COMPANY | 4-hydroxycoumarin-3-carboxamides for the treatment of non-insulin dependent diabetes mellitus |
JP2000080047A (ja) | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
US6214381B1 (en) | 1998-09-08 | 2001-04-10 | Effcon, Inc. | Methazolamide composition and method of use |
WO2001047509A2 (en) * | 1999-12-24 | 2001-07-05 | Smithkline Beecham P.L.C. | Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions |
GB9930688D0 (en) * | 1999-12-24 | 2000-02-16 | Smithkline Beecham Plc | Novel method of treatment |
EP1309324B1 (en) * | 2000-07-07 | 2006-03-22 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
US6946243B2 (en) | 2000-07-20 | 2005-09-20 | Solvay Pharmaceuticals Gmbh | Method of identifying compounds suitable for treatment and/or prophylaxis of obesity |
DE10035227A1 (de) | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
DE10038022A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Inverse Thiazolylamid-Derivate |
EP1307185B1 (en) * | 2000-08-11 | 2005-04-13 | Einar Stefansson | Use of carboanhydrase inhibitors for the prevention of diabetic retinopathy in diabetics |
FR2816841B1 (fr) * | 2000-11-22 | 2004-02-06 | Lipha | Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation |
ES2234925T3 (es) * | 2000-12-22 | 2005-07-01 | Dow Global Technologies, Inc. | Espumas de copolimero de propileno. |
ATE341343T1 (de) * | 2000-12-26 | 2006-10-15 | Sankyo Co | Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel |
CA2364985A1 (en) | 2001-12-14 | 2003-06-14 | John W. Gillard | Imidazo(2,1-b)thiadiazole sulfonamides |
EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
WO2004063194A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
JP2006520335A (ja) | 2003-03-18 | 2006-09-07 | ノバルティス アクチエンゲゼルシャフト | 脂肪酸とアミノ酸を含有する組成物 |
MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
TW200526678A (en) * | 2003-08-01 | 2005-08-16 | Janssen Pharmaceutica Nv | Substituted indole-O-glucosides |
ATE551997T1 (de) | 2003-09-12 | 2012-04-15 | Merck Serono Sa | Sulfonamid-derivate zur behandlung von diabetes |
US20050197376A1 (en) * | 2004-03-02 | 2005-09-08 | Fujisawa Pharmaceutical Co. Ltd. | Concomitant drugs |
RU2395503C2 (ru) | 2004-05-19 | 2010-07-27 | Зольвай Фармасьютиклз Гмбх | Лекарственные средства, содержащие n-сульфамоил-n'-арилпиперазины, предназначенные для профилактики или лечения ожирения и связанных с ним состояний |
WO2007030375A2 (en) | 2005-09-08 | 2007-03-15 | Children's Hospital Medical Center | Lysosomal acid lipase therapy for nafld and related diseases |
US7670794B2 (en) * | 2005-11-04 | 2010-03-02 | Washington University | Managing glycemia status in diabetic patients |
US20070110707A1 (en) * | 2005-11-04 | 2007-05-17 | Washington University | Method of treating diseases involving non-enzymatic glycation |
AR057570A1 (es) * | 2005-11-14 | 2007-12-05 | Solvay Pharm Gmbh | Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o |
ES2356841T3 (es) * | 2005-11-14 | 2011-04-13 | Abbott Products Gmbh | N-sulfamoil-n-benzopiranpiperidinas en calidad de inhibidores de anhidrasas carbónicas. |
JP2009518366A (ja) | 2005-12-09 | 2009-05-07 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症及び関連病状の予防又は治療のための、新規なn−スルファモイル−ピペリジンアミド |
WO2007114948A2 (en) | 2006-04-04 | 2007-10-11 | The Brigham And Women's Hospital, Inc. | Methods and compositions for inhibiting cell death |
NZ579229A (en) | 2007-01-25 | 2011-07-29 | Verva Pharmaceuticals Ltd | Insulin sensitisers and methods of treatment |
WO2011002011A1 (ja) | 2009-07-01 | 2011-01-06 | キッセイ薬品工業株式会社 | Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬 |
CN103068400A (zh) | 2010-06-25 | 2013-04-24 | 阿斯顿大学 | 具有脂类动员性质的糖蛋白及其治疗用途 |
US8937055B2 (en) | 2010-07-15 | 2015-01-20 | Takeda Pharmaceutical Company Limited | Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action |
MX2014014316A (es) | 2012-05-24 | 2015-07-06 | Verva Pharmaceuticals Ltd | Método de reducción de peso. |
NZ702645A (en) | 2012-05-24 | 2016-08-26 | Verva Pharmaceuticals Ltd | A method of improving liver function |
-
2008
- 2008-01-25 NZ NZ579229A patent/NZ579229A/en not_active IP Right Cessation
- 2008-01-25 CA CA2676051A patent/CA2676051C/en not_active Expired - Fee Related
- 2008-01-25 PT PT87003851T patent/PT2106260T/pt unknown
- 2008-01-25 AU AU2008209320A patent/AU2008209320B2/en not_active Ceased
- 2008-01-25 PL PL08700385T patent/PL2106260T3/pl unknown
- 2008-01-25 WO PCT/AU2008/000089 patent/WO2008089521A1/en active Application Filing
- 2008-01-25 ES ES08700385.1T patent/ES2660170T3/es active Active
- 2008-01-25 EP EP08700385.1A patent/EP2106260B8/en not_active Not-in-force
- 2008-01-25 NO NO08700385A patent/NO2106260T3/no unknown
- 2008-01-25 US US12/524,146 patent/US8455432B2/en not_active Expired - Fee Related
- 2008-01-25 JP JP2009546616A patent/JP5301465B2/ja not_active Expired - Fee Related
- 2008-01-25 CN CN200880005674.3A patent/CN101801375B/zh not_active Expired - Fee Related
-
2013
- 2013-05-31 US US13/907,717 patent/US9452148B2/en not_active Expired - Fee Related
-
2016
- 2016-09-26 US US15/276,013 patent/US10172837B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US9452148B2 (en) | 2016-09-27 |
EP2106260B1 (en) | 2017-12-06 |
US20110003740A1 (en) | 2011-01-06 |
AU2008209320B2 (en) | 2013-05-30 |
CA2676051C (en) | 2017-06-06 |
CN101801375A (zh) | 2010-08-11 |
CN101801375B (zh) | 2014-01-01 |
WO2008089521A1 (en) | 2008-07-31 |
US20140011848A1 (en) | 2014-01-09 |
ES2660170T3 (es) | 2018-03-21 |
EP2106260A1 (en) | 2009-10-07 |
EP2106260A4 (en) | 2010-05-26 |
CA2676051A1 (en) | 2008-07-31 |
JP2010516711A (ja) | 2010-05-20 |
NZ579229A (en) | 2011-07-29 |
US10172837B2 (en) | 2019-01-08 |
JP5301465B2 (ja) | 2013-09-25 |
AU2008209320A1 (en) | 2008-07-31 |
NO2106260T3 (pl) | 2018-05-05 |
EP2106260B8 (en) | 2018-04-04 |
US20170079960A1 (en) | 2017-03-23 |
PT2106260T (pt) | 2018-03-05 |
US8455432B2 (en) | 2013-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1600057I1 (hu) | Kezelési eljárások ammónia-megkötõ hatóanyag alkalmazásával | |
IL208354A0 (en) | Methods of treatment | |
IL210856A0 (en) | Combination therapy for the treatment of diabetes and related conditions | |
IL205836A0 (en) | Treatment of interstitial cystitis | |
HK1173654A1 (zh) | 治療化合物及相關的使用方法 | |
EP2334315A4 (en) | MEANS AND METHOD OF TREATMENT TREATMENT | |
EP2300011A4 (en) | METHODS AND THERAPEUTIC COMPOUNDS | |
ZA201106730B (en) | Methods of treatment using combination therapy | |
EP2543383B1 (en) | Macrocyclic compounds and treatment methods | |
GB0807018D0 (en) | Antibodies and treatment | |
HRP20181877T1 (hr) | Postupci za liječenje lijekovima koji uklanjaju amonijak | |
PL2106260T3 (pl) | Środki uwrażliwiające na insulinę i sposoby leczenia | |
HK1153465A1 (zh) | 大環化合物和治療方法 | |
EP2470020A4 (en) | BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH | |
EP2164494A4 (en) | Methods of Treatment | |
EP2124950A4 (en) | PAIN TREATMENT WITH NALOXONE | |
GB0723100D0 (en) | Treatment of HFnEF | |
EP2328908A4 (en) | TREATMENT OF AMYLOIDOSES BASED ON MYELIN BASED PROTEIN AND FRAGMENTS THEREOF | |
ZA200905135B (en) | Insulin sensitisers and methods of treatment | |
EP2203432A4 (en) | PROCESSING METHOD | |
GB0803515D0 (en) | Medicament and method of treatment | |
SI2330892T1 (sl) | Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amoniak | |
GB0700969D0 (en) | Methods of treatment | |
GB0800556D0 (en) | Method of treatment and treatment therefor | |
GB0722706D0 (en) | Cancer treatment medicament use and method of manufacture thereof |